 There have been objections to the implementation and interpretation of this project, most notably by Gilbert et al. (2016), who took issue with the extent to which the replications studies were indeed direct replications. For example, Gilbert et al. highlighted 6 specific examples of “low fidelity protocols”, that is, where replication studies differed in their view substantially from the original (in one case, using a European sample rather than a US sample of participants). However, Anderson et al. (2016) explained in a reply that in half of those cases, the authors of the original study had endorsed the replication as being direct or close to on relevant dimensions and that furthermore, that independently rated similarity between original and replication studies failed to predict replication success. Others (e.g., Etz &amp; Vandekerckhove 2016) have applied Bayesian reanalysis to the OSC’s (2015) data and conclude that up to 75% (as opposed to the OSC’s 36–47%) of replications could be considered successful. However, they do note that in many cases this is only with very weak evidence (i.e., Bayes factors of &lt;10). They too conclude that the failure to reproduce many effects is indeed explained by the overestimation of effect sizes, itself a product of publication bias. A Reproducibility Project: Cancer Biology (also coordinated by the Center for Open Science) is currently underway (Errington et al. 2014), originally attempting to replicate 50 of the highest impact studies in Cancer Biology published between 2010–2012. This project has recently announced it will complete with only 18 replication studies, as too few originals reported enough information to proceed with full replications (Kaiser 2018). Results of the first 10 studies are reportedly mixed, with only 5 being considered “mostly repeatable” (Kaiser 2018).